Schrödinger, Inc. SDGR
At closeNov 3, 2026, 5:18 PM EST
After hours · Nov 3, 5:18 PM ET
- YTD
- +52.01%
- 1 year
- +32.26%
- Market cap
- 2.03B
- Revenue (ttm)
- 259.04M
- Profit margin
- -20.98%
- EPS (ttm)
- -0.74
- Shares out
- 65.64M
- Forward P/E
- -20.13
- YTD return
- +52.01%
- 1-year return
- +32.26%
- Volume
- 1.21M
- Avg volume
- 2.00M
- Open
- 26.47
- Previous close
- 26.19
- Day's range
- 26.42 – 27.94
- 52-week range
- 10.95 – 33.78
- Beta
- 1.65
- Analysts
- Buy
- Price target
- 25.86 (-4.9%)
- Earnings date
- Nov 4, 2026
2Y +8.94 (+49.01%)
Key statistics
- Enterprise value
- 1.65B
- PEG ratio
- 0.00
- Price / sales
- 7.85
- Price / book
- 6.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 7.50%
- Free cash flow
- -29.16M
- Total cash
- 413.74M
- Total debt
- 108.00M
- Return on equity
- -16.17%
- Short % of float
- 24.79%
- 50-day average
- 25.09
- 200-day average
- 16.80
Analyst view
Consensus: buy
- Target (low)
- 17.00
- Target (mean)
- 25.86
- Target (high)
- 32.00
- Strong buy0
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -0.66648 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | -0.41449 | 0.08 | +0.49 | +119.30% |
| May 5, 2026 | Mar 31, 2026 | -0.56 | -0.81 | -0.25 | -44.64% |
| Feb 25, 2026 | Dec 31, 2025 | -0.13 | 0.44 | +0.57 | +438.46% |
| Nov 5, 2025 | Sep 30, 2025 | -0.75 | -0.45 | +0.30 | +40.00% |
| Aug 6, 2025 | Jun 30, 2025 | -0.83 | -0.59 | +0.24 | +28.92% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2026 | UBS | main | Neutral | Neutral |
| Oct 16, 2026 | Keybanc | main | Overweight | Overweight |
| Oct 13, 2026 | TD Cowen | main | Buy | Buy |
| Oct 12, 2026 | BMO Capital | main | Outperform | Outperform |
| May 14, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Apr 8, 2026 | Keybanc | main | Overweight | Overweight |
About Schrödinger, Inc.
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- schrodinger.com
News
10 Health Care Stocks Whale Activity In Today’s Session 
Earnings Preview: Schrodinger, Inc. (SDGR) Q3 Earnings Expected to Decline 
Schrödinger to Present at UBS Global Healthcare Conference 
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
UBS Maintains Neutral on Schrodinger, Raises Price Target to $21 
Schrodinger, Inc. $SDGR Shares Newly Purchased by Counterpoint Mutual Funds LLC 
Keybanc Maintains Overweight on Schrodinger, Raises Price Target to $32 
Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry 
TD Cowen Maintains Buy on Schrodinger, Raises Price Target to $31 
BMO Capital Maintains Outperform on Schrodinger, Raises Price Target to $30
Your note
Sign in to keep a note on SDGR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABEL ROBERT LORNE | Officer | Sale | Mar 3, 2026 | 55,897 |
| AKINSANYA-AKIWUMI KAREN OLUFUNMILYO | Officer | Sale | Sep 16, 2026 | 69,956 |
| AKLIAN MANNIX VARTAN | Officer | Stock Award(Grant) | Mar 1, 2026 | 31,193 |
| FRIESNER RICHARD A | Director | Stock Gift | Jun 25, 2026 | 0 |
| HERMAN JENNY | Officer | Sale | Mar 5, 2026 | 34,804 |
| JAIN RACHIT | Chief Financial Officer | Sale | Jul 15, 2026 | 50,877 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.05% | 10,521,724 | 285.98M | Jun 29, 2026 |
| Gates Foundation Trust | 10.65% | 6,981,664 | 189.76M | Jun 29, 2026 |
| Rubric Capital Management LP | 9.76% | 6,400,000 | 173.95M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.78% | 3,787,391 | 102.94M | Jun 29, 2026 |
| Amova Asset Management Americas Inc | 4.13% | 2,706,143 | 73.55M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.11% | 2,691,149 | 73.15M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.18% | 3,398,299 | 92.37M | Sep 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 3.43% | 2,245,494 | 61.03M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.00% | 1,965,067 | 53.41M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.30% | 1,506,155 | 40.94M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.18% | 1,426,780 | 38.78M | Jun 29, 2026 |
| MFS SERIES TRUST I-MFS New Discovery Fund | 1.38% | 906,770 | 24.65M | Aug 30, 2026 |